□ The Daegu Gyeongbuk Institute of Science & Technology (DGIST; President Kunwoo Lee) and Institut Pasteur Korea (CEO Sungkey Jang) signed a memorandum of understanding (MOU) for “exchanges and collaboration in the AI-based drug screening/identification and drug development industries” at 2:00 p.m. on September 5 (Fri) in the Large Conference Room, Institut Pasteur Korea (Pangyo, Gyeonggi Province). □ With this MOU, the organizations will establish a collaboration system covering exchanges of human resources, materials, information, and research activities, and prepare a common foundation for advancing AI-based drug development to meet a variety of unmet medical needs, including new and variant infectious diseases, aging, cancer, and inflammatory diseases. □ “DGIST has been closely connecting job-oriented human resources development, collaborative research, technology transfer, and commercialization based on the strengths of multidisciplinary research and industry–academia collaboration,” said Director Jaehyung Koo of the Office of Research & University–Industry Collaboration at DGIST. “With this MOU, we will actively promote the discovery of collaborative projects and exchanges between human resources and contribute to creating an AI-based drug development ecosystem and strengthening competitiveness in the regional and national bioindustry by advancing ongoing projects.”□ “We will create new drug candidates by combining our core technology of a cell-based ultra-fast drug effect screening system combined with AI to precisely screen and optimize effective compounds,” said CEO Sungkey Jang of Institut Pasteur Korea. □ Furthermore, Institut Pasteur Korea is a research institute specializing in infectious diseases and focuses on basic and translational research on the development of infectious disease treatments and vaccines based on its state-of-the-art research competencies.